The power to make the difference

Reduce the risk of progression of Barrett's esophagus (BE) with proven treatment.2

Treatment with radiofrequency ablation (RFA) can lead to significantly improved outcomes for patients with Barrett's esophagus (BE), including:

  • Up to 94% reduction in the relative risk of disease progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC)1
  • RFA can reduce absolute risk of progression from confirmed LGD to HGD/EAC by 25% compared to surveillance (NNT=4)1

Stages of the disease

Barrett's Esophagus - Nondysplastic

Non-dysplastic Barrett's esophagus

Barrett's Esophagus - Low grade dysplasia

Low-grade dysplasia

Barrett's Esophagus - High grade dysplasia

High-grade dysplasia

Barrett's Esophagus - Esophageal adenocarcinoma

Esophageal adeno-carcinoma

  • Endoscopic ablation therapy has proved to be more effective than surveillance.1

 

  • Radiofrequency ablation (RFA) has been shown to be a good option for the treatment of patients with LGD and HGD with low rate of complications and good cost-effective results.9

 

  • Moreover, the use of RFA for the treatment of patients with confirmed LGD has shown a significant reduction in progression to HGD and EAC in one randomized trial.1

 

  • The proprietary technology in Barrx™ radiofrequency ablation systems is designed to remove the Barrett’s epithelium without significant injury to the underlying tissue.10

 

  • ESGE guidelines support the use of radiofrequency ablation in the treatment guidelines for dysplastic Barrett's esophagus.11

Why Barrx™ RFA

Medtronic is committed to saving patients’ lives by helping you work towards better patient outcomes and prevent disease progression, with our reliable treatments.

View the product catalogue (open in new window)

One generator. Multiple solutions.

The Barrx™ radiofrequency ablation system includes a bipolar radiofrequency energy generator designed to precisely control depth and uniformity of tissue ablation in the GI tract.

The Barrx™ flex RFA energy generator provides the flexibility to choose either a Barrx™ 360 RFA balloon catheter or a Barrx™ 360 express RFA balloon catheter for larger circumferential treatment areas or a Barrx™ RFA focal catheter for treatment of smaller focal areas.

View the value analysis dossier (open in new window)

Easier

  • Seamless transition between circumferential and spot treatment cases

Faster

  • Rapid delivery of ablative energy for reduced procedure time
  • Ready to deliver next dose in < 2 seconds with Barrx™ 90 RFA focal catheters

Smarter

  • Automatically recommends ablation catheter sizing
  • Tracks and displays total number of ablations
  • Automatically adjusts default power density settings to match catheter
  • Platform for future clinical and product innovation*

Barrx™ RFA in action

Barrx™ RFA is a proven, effective and durable therapy.4

How does it work - a safe and effective treatment for Barrett's esophagus

This quick guide explains which catheters to use for each condition (Barrett's esophagus, GAVE, Radiation proctitis) and the respective ablation/cleaning protocols and energy settings.

Download the quick guide (open in new window)

Barrx™ RFA simulator app

Barrx™ radiofrequency ablation system simulator application for iPad®

The Barrx™ 360 express RFA balloon catheter and the Barrx™ channel RFA endoscopic catheter simulator application is now available on the Apple App Store®.  

This educational application offers an interactive experience that provides useful information about procedural steps, handling, and usage of these devices — in a 3D simulated environment.‡

This app is suitable for iPad®, and is free to download and install.

Download now (open in new window)

Clinical evidence

Many publications demonstrate the efficacy of Barrx™ RFA for the treatment of Barrett's esophagus.

  • Clinical studies have demonstrated the safety and efficacy of RFA for treating all grades of Barrett's esophagus.2,3
  • Multiple trials have shown that treatment with RFA in dysplastic BE patients is safe. RFA is associated with low rates of esophageal strictures and low incidence of buried intestinal metaplasia5,6
  • Barrx™ RFA is effective in patients with confirmed low-grade dysplasia and high-grade dysplasia without visible abnormalities7
  • Barrx™ RFA results in complete eradication of dysplasia in 80-90% of patients with BE8
Radiofrequency ablation versus endoscopic surveillance for patients with Barrett’s esophagus and low-grade dysplasia: a randomized clinical trial.

Conclusion: 
The rate of neoplastic progression to high-grade dysplasia and adenocarcinoma is significantly reduced by RFA. RFA therapy should be considered in patients with a confirmed diagnosis of low-grade dysplasia.

Authors: Phoa K, van Vilsteren FI, Weusten BM, et al.
Published in: American Medical Association (JAMA) 2014;311:1209-1217.

View the clinical evidence (open in new window)

Clinical education

 

Explore our clinical education offering on Medtronic Academy.

 

Barrett's Esophagus: An undiagosed disease

Watch the online webinar.

Reviews and recognition

Listen to expert testimonials and patient stories.

Barrx™ RFA support

Customer technical helpline: 01452 223217
Email: rs.gi-support@medtronic.com

A dedicated support center for the solution of technical issues.

Customer technical service center for gastrointestinal & hepatology products.

 

Interested in learning more?

Contact us to learn more about our product solutions and how our portfolio could benefit you and your patients.

Contact us (open in new window)